

What is claimed is:

1. A pharmaceutical composition for preventing or treating an HIV infection in a patient comprising a hyaluronidase enzyme.
2. A method for preventing or treating an HIV infection in a patient comprising administering to a patient in need of HIV prevention or treatment the pharmaceutical composition of claim 1.
3. A pharmaceutical composition for preventing or treating an HIV infection in a mammal comprising a hyaluronidase treated HIV virus.
4. A pharmaceutical composition according to claim 3 wherein the virus is inactivated or attenuated by heat treatment or chemical treatment.
5. A pharmaceutical composition according to claim 4 wherein the virus is inactivated or attenuated using aldrathiol-2 chemical treatment.
6. A method for preventing or treating an HIV infection in a patient comprising administering to a patient in need of HIV prevention or treatment the pharmaceutical composition of claim 3.
7. A method according to claim 6 wherein the virus is inactivated or attenuated by heat treatment or chemical treatment.
8. A method according to claim 7 wherein the virus is inactivated or attenuated using aldrathiol-2 chemical treatment.
9. A pharmaceutical composition for preventing or treating an HIV infection in a mammal comprising an anti-HIV infection amount of antigen presenting cells that have been sensitized with hyaluronidase treated HIV infected cells.

10. The pharmaceutical composition of claim 9 wherein antigen presenting cells are selected from the group consisting of macrophages and monocytes.

11. A pharmaceutical composition for preventing or treating an HIV infection in a mammal comprising an anti-HIV infection amount of antigen presenting cells that have been sensitized with hyaluronidase treated HIV virus.

12. The pharmaceutical composition of claim 11 wherein the antigen presenting cells are selected from the group consisting of macrophages and monocytes.

13. A method for preventing or treating an HIV infection in a patient comprising administering to a patient in need of HIV prevention or treatment the pharmaceutical composition of claim 9.

14. The method of claim 13 wherein the antigen presenting cells are selected from the group consisting of macrophages and monocytes.

15. A method for preventing or treating an HIV infection in a patient comprising administering to a patient in need of HIV prevention or treatment the pharmaceutical composition of claim 11.

16. The method of claim 15 wherein the antigen presenting cells are selected from the group consisting of macrophages and monocytes.

17. An anti-HIV vaccine comprising a hyaluronidase treated HIV virus.

18. The anti-HIV vaccine of claim 17 wherein the HIV virus is inactivated or attenuated by heat treatment or chemical treatment.

19. The anti-HIV vaccine of claim 18 wherein the virus is inactivated or attenuated using aldrathiol-2 chemical treatment.

20. A method of inducing or enhancing an immune response in a patient, the method comprising administering to the patient the anti-HIV vaccine of claim 17.

21. The method of claim 20 wherein the virus is inactivated or attenuated by heat treatment or chemical treatment.

22. The method of claim 21 wherein the virus is inactivated or attenuated using aldrathiol-2 chemical treatment.

23. A method of inducing or enhancing immunity in a patient in need of such treatment in order to initiate responses to otherwise self or host lineage altered cells, antigens or immunogens the method comprising administering to said patient a hyaluronidase enzyme.

24. A pharmaceutical composition used to initiate immune responses to pathogens or pathogen infected cells in a patient in need of such treatment comprising a hyaluronidase enzyme.